Journal
EUROPEAN JOURNAL OF HAEMATOLOGY
Volume 94, Issue 6, Pages 554-557Publisher
WILEY
DOI: 10.1111/ejh.12396
Keywords
Brentuximab Vedotin; cytokine release syndrome; anaplastic large cell lymphoma; infusion reaction; CD30
Categories
Ask authors/readers for more resources
Brentuximab Vedotin is an antibody - drug conjugate targeting CD30. We report a case of severe cytokine release syndrome (CRS) after administration of the first dose of Brentuximab Vedotin in a 64-yr-old patient with relapsed systemic anaplastic large cell lymphoma (sALCL). To our knowledge, this is the first case of CRS to Brentuximab Vedotin described in the literature. However, CRS to Brentuximab Vedotin might be underestimated, as the drug has not been tested in large phase III trials yet.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available